Evidence map›Paper›PMID 42615414›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2026

Selective pharmacological blockade of GPR39 markedly reduces no-reflow and infarct volumes in rat acute myocardial infarction when administered before reperfusion.

Carmen Methner, Mary Plascencia, Allura Thompson, Lijuan Liu, Masaki Kajimoto, D Elizabeth Le, Agostino Cianciulli, Annalisa Pellacani, Jessica Franchi, Chiara Marcheselli and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Carmen MethnerKnight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, United States.
Mary PlascenciaKnight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, United States.
Allura ThompsonKnight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, United States.ORCID 0009-0003-7196-6275
Lijuan LiuDepartment of Anesthesia and Perioperative Medicine, Oregon Health & Science University, Portland, Oregon, United States.
Masaki KajimotoKnight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, United States.ORCID 0000-0001-9377-1354
D Elizabeth LeKnight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, United States.ORCID 0000-0002-3921-0692
Agostino CianciulliThe Medical Research Center, Aptuit (Evotec), Verona, Italy.
Annalisa PellacaniThe Medical Research Center, Aptuit (Evotec), Verona, Italy.
Jessica FranchiThe Medical Research Center, Aptuit (Evotec), Verona, Italy.
Chiara MarcheselliThe Medical Research Center, Aptuit (Evotec), Verona, Italy.
Alberto ParazzoliThe Medical Research Center, Aptuit (Evotec), Verona, Italy.
Fabrizio MicheliThe Medical Research Center, Aptuit (Evotec), Verona, Italy.ORCID 0000-0002-1871-5288
Sanjiv KaulKnight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon, United States.ORCID 0000-0003-0124-3920

Funding

Oregon Community Foundation (OCF)
6 · The paper itself

Abstract

Our aim was to determine whether selective pharmacological blockade of G protein-coupled receptor 39 (GPR39) by the novel drug, VC108, reduces no-reflow (NRV) and infarct (INV) volumes during acute myocardial infarction (AMI). Immunocytochemistry and quantitative polymerase chain reaction (qPCR) of isolated rat cardiac cells as well as immunohistochemistry and Western blot of rat myocardium were performed for presence of GPR39. Rats underwent 1 h of coronary occlusion and 1 h of reperfusion.

Indexed as

Myocardial InfarctionMyocardial Reperfusion InjuryNo-Reflow PhenomenonReceptors, G-Protein-CoupledAnimalsApoptosisBenzodioxolesDisease Models, AnimalMaleMyocardiumMyocytes, CardiacQuinolinesRatsRats, Sprague-Dawley4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinolineBenzodioxolesGper1 protein, ratQuinolinesReceptors, G-Protein-CoupledGPR39no-reflowVC108

Identifiers

PMID42615414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.